Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Authors
Discussion
Loading...
Member takes
Implication
Randomized double-blind trials demonstrate sustained relief with biweekly and monthly lebrikizumab in moderate-to-severe atopic dermatitis, supporting flexible maintenance dosing regimens.
Key Points
- To assess the 52-week efficacy and safety of maintenance lebrikizumab administered every two or four weeks following a 16-week induction period in patients with moderate-to-severe atopic dermatitis.
- Conducted two 52-week, randomized, double-blind, placebo-controlled phase III trials.
- Administered lebrikizumab every two weeks (Q2W) during an initial 16-week induction phase.
- Assigned patients who completed induction to maintenance lebrikizumab regimens dosed either every two weeks (Q2W) or every four weeks (Q4W).
- Both lebrikizumab Q2W and Q4W maintenance regimens maintained improvements in the signs and symptoms of moderate-to-severe atopic dermatitis through 52 weeks (numerical values not reported).
- Safety profiles through week 52 were consistent with previously published safety observations for lebrikizumab.
Cite This Study
Blauvelt et al. (2023) studied this question.